Tumor individualized immunotherapy gene detection result interpretation method and system and storage medium

Abstract

The invention discloses a tumor individualized immunotherapy gene detection result interpretation method and system and a storage medium. According to the interpretation method, mutation in gene detection can be classified and graded, targeted drug information related to gene mutation and chemotherapeutic drug information related to germline mononucleotide polymorphism are interpreted, clinical test information meeting conditions is recommended in a personalized mode in combination with a gene detection result of a patient, and the result is displayed in a visual mode. The method comprises interpretation of most currently known biomarkers related to tumor immunotherapy prognosis, comprehensive guidance information including tumor immunotherapy, targeted therapy, chemotherapy and clinical trials can be provided for a patient at a time, meanwhile, interpretation results are visually displayed, and the method is more visual, simpler and convenient for the patient to understand.

Description

technical field [0001] The invention relates to the field of gene detection, in particular to a method, system and storage medium for interpreting gene detection results of tumor individualized immunotherapy. Background technique [0002] With the development of genetic testing technology, the use of genetic testing to guide precision medicine in the treatment of cancer patients is becoming more and more widely used. However, the products of most genetic testing institutions are mainly limited to the detection and interpretation of targeted therapy and chemotherapy. In recent years, tumor immunotherapy has developed rapidly. Eight immune checkpoint inhibitors have been approved in China, and more than 200 phase I-III clinical trials of tumor immunotherapy are underway in China. Unlike other anti-tumor treatment options, tumor immunotherapy can bring lasting benefits to patients and is a promising treatment option. Cancer patients receiving tumor immunotherapy also need prec...

AI Technical Summary

Problems solved by technology

[0003] (1) Limitations in the interpretation range of indicators related to tumor immunotherapy prognosis: most products currently only include the interpretation of tumor mutation burden (TMB), PD-L1 expression, and microsatellite instability (MSI), lacking other indicators that are closely related to the prognosis of tumor immunotherapy Relevant indicators include CD8TILs, an indicator of immune cell infiltration in tumor tissue, HLA heterozygosity loss status of tumor immune escape related indicators, and positive and negative tumor immune related gene mutations (positive and negative related gene mutations include treatment resistance and hyperprogression related indicators)

[0004] (2) The results of many prognosis-related indicators of tumor immunotherapy are not clear and intuitive: most products currently only provide written descriptions of indicators related to the prognosis of immunotherapy, but there are many prognostic indicators of tumor immunotherapy, which cannot be clearly and intuitively viewed by customers. to the overall state of each indicator, making it difficult to interpret the results

Images